Suppr超能文献

在 2b 期 GLIMMER 试验中原发性胆汁性胆管炎参与者中瘙痒与睡眠的关系。

Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.

机构信息

GSK, London, UK.

University of Texas Southwestern Medical Center, Dallas, TX, USA.

出版信息

J Patient Rep Outcomes. 2024 Jun 12;8(1):60. doi: 10.1186/s41687-024-00722-y.

Abstract

BACKGROUND

Cholestatic pruritus and fatigue are debilitating conditions associated with primary biliary cholangitis (PBC) and can significantly impact patients' quality of life. Pruritus in PBC often worsens at night and patients frequently report sleep disturbance, which contributes to cognitive symptoms and fatigue. Linerixibat is an ileal bile acid transporter inhibitor in clinical development for the treatment of pruritus associated with PBC and was recently assessed versus placebo in the Phase 2b GLIMMER trial. This post-hoc analysis assesses the relationship between pruritus severity and sleep disturbance in participants of GLIMMER regardless of treatment group.

METHODS

GLIMMER (NCT02966834), a multicenter, double-blind, randomized, placebo-controlled trial, recruited 147 patients with PBC and moderate-to-severe pruritus. Following 4 weeks single-blind placebo, patients (randomized 3:1) received linerixibat or placebo for 12 weeks (to Week 16). Participants graded their itch (twice daily) and its interference with sleep (once daily) in an electronic diary using a 0-10 numerical rating scale (NRS). Weekly and monthly itch scores were calculated as the mean of the worst daily itch score over the respective time period. At study visits, participants completed the 5-D itch scale and the PBC-40 quality of life questionnaire, both of which contain an item specific to itch-related sleep disturbance. The impact of pruritus on sleep was assessed post hoc through correlations between the changes in NRS, 5-D itch, and PBC-40.

RESULTS

Strong correlations were found between change from baseline in weekly itch and sleep NRS scores (r = 0.88 [95% confidence interval (CI): 0.83; 0.91]) at the end of treatment (Week 16), as well as in monthly itch and sleep NRS scores (r = 0.84 [95% CI: 0.80; 0.87]). Patients with improved weekly pruritus score severity category demonstrated reduced perceived sleep interference on average. Itch responders (≥2-point improvement in weekly itch score from baseline) displayed larger improvements in weekly sleep NRS score, 5-D itch, and PBC-40 sleep items, than itch non-responders (<2-point improvement).

CONCLUSIONS

A strong correlation exists between changes in pruritus severity and sleep interference in patients with PBC; pruritus reduction could generate concomitant improvement in sleep.

摘要

背景

瘙痒和疲劳是原发性胆汁性胆管炎(PBC)患者的两种致残症状,会显著影响患者的生活质量。PBC 患者的瘙痒通常在夜间加重,且常伴有睡眠障碍,这导致了认知症状和疲劳。Linerixibat 是一种正在开发中的回肠胆汁酸转运蛋白抑制剂,用于治疗 PBC 相关瘙痒,最近在 2b 期 GLIMMER 试验中与安慰剂进行了比较。这项事后分析评估了 GLIMMER 参与者中瘙痒严重程度与睡眠障碍之间的关系,无论治疗组如何。

方法

GLIMMER(NCT02966834)是一项多中心、双盲、随机、安慰剂对照试验,招募了 147 名患有 PBC 和中重度瘙痒的患者。在 4 周的单盲安慰剂期后,患者(按 3:1 随机)接受 linerixibat 或安慰剂治疗 12 周(至第 16 周)。参与者使用电子日记以 0-10 数字评分量表(NRS)每天两次记录瘙痒(两次)及其对睡眠的干扰(一次)。每周和每月的瘙痒评分是通过各自时间段内每日最严重瘙痒评分的平均值计算得出的。在研究访视时,参与者使用包含瘙痒相关睡眠障碍特定项目的 5-D 瘙痒量表和 PBC-40 生活质量问卷完成瘙痒评分。通过 NRS、5-D 瘙痒和 PBC-40 的变化之间的相关性,对瘙痒对睡眠的影响进行了事后评估。

结果

在治疗结束时(第 16 周),每周瘙痒与睡眠 NRS 评分的变化之间存在很强的相关性(r=0.88[95%置信区间(CI):0.83;0.91]),每月瘙痒与睡眠 NRS 评分的变化之间也存在很强的相关性(r=0.84[95% CI:0.80;0.87])。每周瘙痒严重程度改善的患者平均睡眠干扰程度降低。瘙痒缓解者(每周瘙痒评分较基线改善≥2 分)在每周睡眠 NRS 评分、5-D 瘙痒和 PBC-40 睡眠项目方面的改善幅度大于瘙痒无缓解者(每周瘙痒评分较基线改善<2 分)。

结论

在 PBC 患者中,瘙痒严重程度的变化与睡眠干扰之间存在很强的相关性;瘙痒减轻可能会同时改善睡眠。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30c/11166618/d04d85c71f69/41687_2024_722_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验